T cell tolerance to tumors and cancer immunotherapy

Advances in Experimental Medicine and Biology

Volumn 601, Issue , 2007, Pages 357-368

  Shafer Weaver, Kimberly ^a   Anderson, Michael ^b   Malyguine, Anatoli ^a   Hurwitz, Arthur A ^b  

^a SAIC FREDERICK INC   (United States)

^b Laboratory of Molecular Immunoregulation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; TUMOR ANTIGEN;

ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; METHODOLOGY; MOUSE; NEOPLASM; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; EPITOPES; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MODELS, BIOLOGICAL; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 34848885218     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72005-0_38     Document Type: Conference Paper

References (62)

1. Abken, H., Hombach, A., Heuser, C., Kronfeld, K. and Seliger, B. (2002) Tuning tumorspecific T cell activation: A matter of costimulation? Trends Immunol 23, 240-245.
2. Anderson, M., Shafer-Weaver, K., Greenberg, N. and Hurwitz, A. (2007) Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 178, 1268-1276.
3. Attia, P., Maker, A., Haworth, L., Rogers-Freezer, L. and Rosenberg, S. (2005a) Inability of a fusion protein of IL-2 and diphtheria toxin to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28, 582-592.
4. Attia, P., Phan, G., Maker, A., Robinson, M., Quezado, M., Yang, J., Sherry, R., Topalian, S., Kammula, U., Royal, R., Restifo, N., Haworth, L., Levy, C., Mavroukakis, S., Nichol, G., Yellin, M. and Rosenberg, S. (2005b) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen-4. J Clin Oncol 23, 6043-6053.
5. Barnett, B., Kryczek, I., Cheng, P., Zou, W. and Curiel, T. (2005) Regulatory T cells in ovarian cancer: Biology and therapeutic potential. Am J Reprod Immunol 54, 369-377.
6. Bennett, S., Carbone, F., Karamalis, F., Flavell, R., Miller, J. and Heath, W. (1998) Help for cytotoxic-T cell responses is mediated by CD40 signalling. Nature 393, 478-480.
7. Berkow, R. and Beers, M. (1997). Cancer and the immune system. The Merck Manual of Medical Information. Whitehouse Station, Merck Research Laboratories: 792-794.
8. Blattman, J. and Greenberg, P. (2004) Cancer immunotherapy: A treatment for the masses. Science 305, 200-205.
9. Bogen, B. (1996) Peripheral T cell tolerance as a tumor escape mechanism: Deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26, 2671-2679.
10. Boon, T. and van Der Bruggen, P. (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183, 725-729.
11. Boshoff, C. and Weiss, R. (2002) AIDS-related malignancies. Nat Rev Cancer 2, 373-382.
12. Challis, G. and Stam, H. (1990) The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol 29, 545-550.
13. Chen, Q., Daniel, V. and Maher, D. (1994) Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56, 755-760.
14. Comes, A., Rosso, O., Orengo, A., Carlo, E.D., Sorrentino, C., Meazza, R., Piazza, T., Valzasina, B., B., Nanni, P., Colombo, M. and Ferrini, S. (2006) CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 176, 1750-1758.
15. Conejo-Garcia, J., Benencia, F., Courreges, M., Kang, E., Mohamed-Hadley, A., Buckanovich, R., Holtz, D., Jenkins, A., Na, H., Wagner, D., Katsaros, D., Caroll, R. and Coukos, G. (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10, 950-958.
16. Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. and Smyth, M. (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing liganddeficient mice. J Immunol 168, 1356-1361.
17. Curiel, T., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M., Knutson, K., Chen, L. and Zou, W. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-949.
18. Gabrilovich, D. (2004) Mechanisms and functional significance of tumour-induced dendriticcell defects. Nat Rev Immunol 4, 941-952.
19. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S. and Carbone, D. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166.
20. Gattinoni, L., Klebanoff, C., Palmer, D., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S., Theoret, M., Rosenberg, S. and Restifo, N. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115, 1616-1626.
21. Gorelik, L. and Flavell, R. (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7, 1118-1122.
22. Granziero, L., Krajewski, S., Farness, P., Yuan, L., Courtney, M., Jackson, M., Peterson, P. and Vitiello, A. (1999) Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol 29, 1127-1138.
23. Greenberg, N., DeMayo, F., Finegold, M., Medina, D., Tilley, W., Aspinall, J., Cunha, G., Donjacour, A., Matusik, R. and Rosen, J. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92, 3439-3443.
24. Huang, B., Pan, P., Li, Q., Sato, A., Levy, D., Bromberg, J., Divino, C. and Chen, S. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumorinduced Treg cells and T cell anergy in tumor-bearing host. Cancer Res 66, 1123-1131.
25. Hurwitz, A., Foster, B., Kwon, E., Truong, T., Choi, E., Greenberg, N., Burg, M. and Allison, J. (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60, 2444-2448.
26. Hurwitz, A. and Ji, Q. (2004) Autoimmune depigmentation following sensitization to melanoma antigens. Methods Mol Med 102, 421-427.
27. Kalams, S. and Walker, B. (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188, 2199-2204.
28. Kaplan, D., Shankaran, V., Dighe, A., Stockert, E., Aguet, M., Old, L. and Schreiber, R. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95, 7556-7561.
29. Khazaie, K. and von Boehmer, H. (2006) The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16, 124-136.
30. Krummel, M. and Allison, J.P. (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183, 2533-2540.
31. Linsley, P., Greene, J., Brady, W., Bajorath, J., Ledbetter, J. and Peach, R. (1994) Human B7- 1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793-801.
32. Liyanage, U., Moore, T. and Joo, H. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169, 2756-2761.
33. Mapara, M. and Sykes, M. (2004) Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22, 1136-1151.
34. Marzo, A., Kinnear, B., Lake, R., Frelinger, J., Collins, E., Robinson, B. and Scott, B. (2000) Tumor-specific CD4+ T cells have a major " post-licensing" role in CTL mediated antitumor immunity. J Immunol 165, 6047-6055.
35. Mathis, D. and Benoist, C. (2004) Back to central tolerance. Immunity 20, 509-516.
36. Melief, C. (2003) Regulation of cytotoxic T lymphocyte responses by dendritic cells: Peaceful coexistence of cross-priming and direct priming? Eur J Immunol 33, 2645-2654.
37. Miyara, M. and Sakaguchi, S. (2007) Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med. 13, 108-116.
38. Molldrem, J., Lee, P., Kant, S., Wieder, E., Jiang, W., Lu, S., Wang, C. and Davis, M. (2003) Chronic myelogenous leukemia shapes host immunity by selective deletion of high-Avidity leukemia-specific T cells. J Clin Invest 111, 639-647.
39. Moretti, S., Pinzi, C., Berti, E., Spallanzani, A., Chiarugi, A., Boddi, V., Reali, U. andGiannotti, B. (1997) In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7, 313-321.
40. Moroz, A., Eppolito, C., Li, Q., Tao, J., Clegg, C. and Shrikant, P. (2004) IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: Comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173, 900-909.
41. Naftzger, C., Takechi, Y., Kohda, H., Hara, I., Vijayasaradhi, S. and Houghton, A. (1996) Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93, 14809-14814.
42. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H. and Ohtani, H. (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58, 3491-3494.
43. Overwijk, W., Lee, D., Surman, D., Irvine, K., Touloukian, C., Chan, C., Carroll, M., Moss, B., Rosenberg, S. and Restifo, N. (1999) Vaccination with a recombinant vaccinia virus encoding a " self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 96, 2982-2987.
44. Rohrer, J., Barsoum, A. and Dyess, D. (1999) Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol , 162, 6880-6892.
45. Rosenberg, S. (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287.
46. Salazar-Onfray, F. (1999) Interleukin-10: A cytokine used by tumors to escape immunosurveillance. Med Oncol 16, 86-94.
47. Schoenberger, S., Toes, R., Voort, E.V.D., Offringa, R. and Melief, C. (1998) T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483.
48. Serafini, P., Borrello, I. and Bronte, V. (2006) Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16, 53-65.
49. Sharma, S., Zhu, L., Yang, S., Zhang, L., Lin, J., Hillinger, S., Gardner, B., Reckamp, K., Strieter, R., Huang, M., Batra, R. and Dubinett, S. (2005) Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 175, 813-819.
50. Shrikant, P., Khoruts, A. and Mescher, M. (1999) CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11, 483-493.
51. Smyth, M., Thia, K., Street, S., MacGregor, D., Godfrey, D. and Trapani, J. (2000) Perforinmediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192, 755-760.
52. Sotomayor, E., Borrello, I., Rattis, F., Cuenca, A., Abrams, J., Staveley-O'Carroll, K. and Levitsky, H. (2001) Cross-presentation of tumor antigens by bone marrow-derived antigen- presenting cells is the dominant mechanism in the induction of T cell tolerance during B cell lymphoma progression. Blood 98, 1070-1077.
53. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D. and Levitsky, H. (1998) Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 95, 1178-1183.
54. Sutmuller, R., Duivenvoorde, L.V., Elsas, A.V., Schumacher, T., Wildenberg, M., Allison, J., Toes, R., Offringa, R. and Melief, C. (2001) Synergism of CTLA-4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194, 823-832.
55. Takeda, K., Smyth, M., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H. and Okumura, K. (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195, 161-169.
56. Tenderich, G., Deyerling, W. and Schulz, U. (2001) Malignant neoplastic disorders following long-term immunosuppression after orthotopic heart transplantation. Transplant. Proc 33, 3653-3655.
57. Tourkova, I., Yamabe, K., Foster, B., Chatta, G., Perez, L., Shurin, G. and Shurin, M. (2004) Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate 59, 203-213.
58. Townsend, S. and Allison, J. (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368-370.
59. van Elsas, A., Hurwitz, A. and Allison, J. (1999) Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190, 355-366.
60. Ward, R., Hawkins, N., Coomber, D. and Disis, M. (1999) Antibody immunity to the HER- 2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 60, 510-515.
61. Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H. and Fu, Y. (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of latestage tumors. J Exp Med 201, 779-791.
62. Zheng, G., Liu, S., Wang, P., Xu, Y. and Chen, A. (2006) Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells. Cancer Res 66, 6793-6799.